Percutaneous Device Closure of Patent Foramen Ovale in Patients With Presumed Cryptogenic Stroke or Transient Ischemic Attack The Mayo Clinic Experience

被引:29
作者
Ford, Monique A. [1 ]
Reeder, Guy S. [1 ]
Lennon, Ryan J. [2 ]
Brown, Robert D. [3 ]
Petty, George W. [3 ]
Cabalka, Allison K. [4 ]
Cetta, Frank [1 ,4 ]
Hagler, Donald J. [1 ,4 ]
机构
[1] Mayo Clin Coll Med, Div Cardiovasc Dis, Rochester, MN USA
[2] Mayo Clin Coll Med, Div Biostat, Rochester, MN USA
[3] Mayo Clin Coll Med, Div Neurol, Rochester, MN USA
[4] Mayo Clin Coll Med, Div Pediat Cardiol, Rochester, MN USA
关键词
patent foramen ovale; cryptogenic stroke; transient ischemic attack; ATRIAL SEPTAL ANEURYSM; PARADOXICAL EMBOLISM; RISK-FACTORS; ECHOCARDIOGRAPHY; CLASSIFICATION; PREVALENCE; DEFECT;
D O I
10.1016/j.jcin.2008.12.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We sought to determine safety, recurrence rates, and novel risk factors for recurrence in patients with cryptogenic stroke/transient ischemic attack (TIA) after patent foramen ovale closure. Background Patent foramen ovale closure in patients with cryptogenic stroke/TIA remains highly controversial. There are limited data on long-term recurrence rates and their predictors in these patients. Methods The records of all patients who underwent patent foramen ovale device closure between December 2001 and June 2006 were reviewed. Patients were seen for clinical follow-up at 3 months then followed annually via telephone. Primary end points were recurrent stroke/TIA. Kaplan-Meier methods were used to estimate recurrent event rates. Cox regression analysis was used to identify risk factors for recurrences. Results There were 352 patients with cryptogenic stroke (n = 225) or TIA (n = 118) with a mean age of 53.4 years. The procedural complication rate was 3.4%. Recurrent events occurred in 8 patients: 7 strokes and 2 TIA, 1 patient had 2 recurrent strokes. The recurrence rate was 0.6% and 2.1% for stroke and 0.3% and 0.7% for TIA at 1 and 4 years, respectively. The combined end point of recurrent stroke/TIA occurred at a rate of 0.9% and 2.8% at 1 and 4 years, respectively. Risk factors for recurrences were elevated pulmonary artery pressure (hazard ratio [HR]: 1.12, p = 0.009), elevated right ventricular pressure (HR: 1.09, p = 0.04), factor V Leiden mutation (HR: 7.42, p = 0.014), and protein S deficiency (HR: 12.2, p = 0.002). Residual shunt and atrial septal aneurysm were not associated with recurrences. Conclusions Patent foramen ovale device closure is safe and is associated with a low recurrence of stroke/TIA. Factors associated with recurrence are thrombophilia and elevated intracardiac pressures. (J Am Coll Cardiol Intv 2009;2:404-11) (C) 2009 by the American College of Cardiology Foundation
引用
收藏
页码:404 / 411
页数:8
相关论文
共 29 条
[11]   Patent foramen ovale and stroke [J].
Homma, S ;
Sacco, RL .
CIRCULATION, 2005, 112 (07) :1063-1072
[12]   Transient ischemic attack [J].
Johnston, SC .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1687-1692
[13]   Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale [J].
Karttunen, V ;
Hiltunen, L ;
Rasi, V ;
Vahtera, E ;
Hillbom, M .
BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 (03) :261-268
[14]   Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli - A systematic review [J].
Khairy, P ;
O'Donnell, CP ;
Landzberg, MJ .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (09) :753-760
[15]   Transcatheter amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism [J].
Khositseth, A ;
Cabalka, AK ;
Sweeney, JP ;
Fortuin, FD ;
Reeder, GS ;
Connolly, HM ;
Hagler, DJ .
MAYO CLINIC PROCEEDINGS, 2004, 79 (01) :35-41
[16]   PREVALENCE OF PATENT FORAMEN OVALE IN PATIENTS WITH STROKE [J].
LECHAT, P ;
MAS, JL ;
LASCAULT, G ;
LORON, P ;
THEARD, M ;
KLIMCZAC, M ;
DROBINSKI, G ;
THOMAS, D ;
GROSGOGEAT, Y .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (18) :1148-1152
[17]   Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. [J].
Mas, JL ;
Arquizan, C ;
Lamy, C ;
Zuber, M ;
Cabanes, L ;
Derumeaux, G ;
Coste, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (24) :1740-1746
[18]   Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: The SPARC study [J].
Meissner, I ;
Whisnant, JP ;
Khandheria, BK ;
Spittell, PC ;
O'Fallon, WM ;
Pascoe, RD ;
Enriquez-Sarano, M ;
Seward, JB ;
Covalt, JL ;
Sicks, JD ;
Wiebers, DO .
MAYO CLINIC PROCEEDINGS, 1999, 74 (09) :862-869
[19]   Outcome of patients with cryptogenic stroke and patent foramen ovale [J].
Nedeltchev, K ;
Arnold, M ;
Wahl, A ;
Sturzenegger, M ;
Vella, EE ;
Windecker, S ;
Meier, B ;
Mattle, HP .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 72 (03) :347-350
[20]   Trends in the use of percutaneous closure of patent foramen ovale and atrial septal defect in adults, 1998-2004 [J].
Opotowsky, Alexander R. ;
Landzberg, Michael J. ;
Kimmel, Stephen E. ;
Webb, Gary D. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (05) :521-522